These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38305000)

  • 21. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
    Mazur NI; Terstappen J; Baral R; Bardají A; Beutels P; Buchholz UJ; Cohen C; Crowe JE; Cutland CL; Eckert L; Feikin D; Fitzpatrick T; Fong Y; Graham BS; Heikkinen T; Higgins D; Hirve S; Klugman KP; Kragten-Tabatabaie L; Lemey P; Libster R; Löwensteyn Y; Mejias A; Munoz FM; Munywoki PK; Mwananyanda L; Nair H; Nunes MC; Ramilo O; Richmond P; Ruckwardt TJ; Sande C; Srikantiah P; Thacker N; Waldstein KA; Weinberger D; Wildenbeest J; Wiseman D; Zar HJ; Zambon M; Bont L
    Lancet Infect Dis; 2023 Jan; 23(1):e2-e21. PubMed ID: 35952703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies.
    Srikantiah P; Vora P; Klugman KP
    Clin Infect Dis; 2021 Sep; 73(Suppl_3):S177-S179. PubMed ID: 34472571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.
    Karron RA; Atwell JE; McFarland EJ; Cunningham CK; Muresan P; Perlowski C; Libous J; Spector SA; Yogev R; Aziz M; Woods S; Wanionek K; Collins PL; Buchholz UJ
    Am J Respir Crit Care Med; 2021 Mar; 203(5):594-603. PubMed ID: 32871092
    [No Abstract]   [Full Text] [Related]  

  • 26. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.
    Shan J; Britton PN; King CL; Booy R
    Influenza Other Respir Viruses; 2021 Jul; 15(4):539-551. PubMed ID: 33764693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
    Browne SK; Beeler JA; Roberts JN
    Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
    Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
    Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventative therapies for respiratory Syncytial virus (RSV) in children: Where are we now?
    Bourassa MH; Lands LC
    Paediatr Respir Rev; 2024 Mar; 49():24-27. PubMed ID: 37704463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
    Scotta MC; Stein RT
    J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
    Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate.
    McGinnes Cullen L; Luo B; Wen Z; Zhang L; Durr E; Morrison TG
    J Virol; 2023 Jan; 97(1):e0190022. PubMed ID: 36602367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children.
    McFarland EJ; Karron RA; Muresan P; Cunningham CK; Perlowski C; Libous J; Oliva J; Jean-Philippe P; Moye J; Schappell E; Barr E; Rexroad V; Fearn L; Cielo M; Wiznia A; Deville JG; Yang L; Luongo C; Collins PL; Buchholz UJ
    J Infect Dis; 2020 Jun; 221(12):2050-2059. PubMed ID: 32006006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
    Huang K; Wu H
    Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants.
    Lanari M; Silvestri M; Rossi GA
    Curr Drug Metab; 2013 Feb; 14(2):216-25. PubMed ID: 22935064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Welliver RC; Papin JF; Preno A; Ivanov V; Tian JH; Lu H; Guebre-Xabier M; Flyer D; Massare MJ; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2020 Jan; 38(5):1258-1270. PubMed ID: 31761502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.